Drug Search Results
More Filters [+]

ARC-19499

Alternative Names: arc-19499, arc19499, arc 19499
Latest Update: 2021-05-05
Latest Update Note: Clinical Trial Update

Product Description

ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood. In the present study, using a monkey model of hemophilia, FVIII neutralization resulted in prolonged clotting times as measured by thromboelastography and prolonged saphenous-vein bleeding times, which are consistent with FVIII deficiency.

Mechanisms of Action: TFP Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ARC-19499

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Hemophilia A

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ARC19499-001

P1

Terminated

Hemophilia A

2011-12-28

22%

Recent News Events

Date

Type

Title